Summary

The sample “Winimed 10” from DEUS Medical underwent qualitative and quantitative analysis. Testing confirmed the presence of Stanozolol with measured concentrations of 9.55 mg in the first pill and 9.86 mg in the second pill.

Testing was ordered and conducted on 18-20 November 2020.


Detailed Report

Product Overview

Sample Acquisition and Testing

Testing Results


Verification Details


Evaluation of Reseller-Submitted Testing

The test confirms the presence of Stanozolol in the Winimed 10 pills with minor dosage variations (9.55 mg and 9.86 mg), which are within acceptable manufacturing tolerances for pharmaceuticals.


Conclusion

The results validate the presence and dosage of Stanozolol in the sample, demonstrating compliance with the expected formulation standards.


Disclaimer

This report is for informational purposes and reflects findings based on reseller-submitted testing. Independent third-party analysis is recommended for thorough validation.